StockData
NeuroPace Inc logo

NeuroPace Inc (NPCE) stock

NPCENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/3028% above fair value
$8.20+0.23 (+2.89%)

Close on Nov 17, 2026Market cap $281.46MP/E –Yield 0.00%

NeuroPace operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

NeuroPace's operating income for the twelve months ending Jun 30, 2026 was -$15.08M. For fiscal 2025 it was -$16.34M. The highest annual figure on record is -$13.05M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$16.34M–
FY2024Dec 31, 2024-$21.67M–
FY2023Dec 31, 2023-$27.17M–
FY2022Dec 31, 2022-$40.79M–
FY2021Dec 31, 2021-$23.74M–
FY2020Dec 31, 2020-$13.05M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.14M–
Q1 FY2026Mar 31, 2026-$5.57M–
Q4 FY2025Dec 31, 2025-$1.77M–
Q3 FY2025Sep 30, 2025-$2.60M–
Q2 FY2025Jun 30, 2025-$8.19M–
Q1 FY2025Mar 31, 2025-$5.15M–
Q4 FY2024Dec 31, 2024-$3.65M–
Q3 FY2024Sep 30, 2024-$4.24M–
Q2 FY2024Jun 30, 2024-$6.23M–
Q1 FY2024Mar 31, 2024-$7.55M–
Q4 FY2023Dec 31, 2023-$5.05M–
Q3 FY2023Sep 30, 2023-$5.95M–
Q2 FY2023Jun 30, 2023-$7.85M–
Q1 FY2023Mar 31, 2023-$8.32M–
Q4 FY2022Dec 31, 2022-$9.86M–
Q3 FY2022Sep 30, 2022-$10.20M–
Q2 FY2022Jun 30, 2022-$10.97M–
Q1 FY2022Mar 31, 2022-$9.76M–
Q4 FY2021Dec 31, 2021-$9.02M–
Q3 FY2021Sep 30, 2021-$6.24M–
Q2 FY2021Jun 30, 2021-$4.61M–
Q1 FY2021Mar 31, 2021-$3.87M–
Q4 FY2020Dec 31, 2020-$2.98M–
Q3 FY2020Sep 30, 2020-$1.17M–
Q2 FY2020Jun 30, 2020-$3.45M–
Q1 FY2020Mar 31, 2020-$5.46M–

More NeuroPace figures

See a number that looks wrong?